Micar21 help Covid-19 science researchers

The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: A Free energy of perturbation study
Link to bioRxiv

The R346K Mutation in the Mu Variant of SARS-CoV-2 Alter the Interactions with Monoclonal Antibodies from Class 2: A Free Energy of Perturbation Study
Link to bioRxiv

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET:

Entire drug discovery process takes 2-8 weeks through our platform Micar21

Micar Innovation novel molecules has non-clinical Proof-of-Concepts achievements in therapeutic areas such as neuroscience, oncology, cardio-vascularity, dermatology, immunology (Pipeline). The business model is based on licensing our intellectual property to commercial partners or on the creation new spin out companies. The demonstration of true clinical proof-of-concept is a key value-creation step in the clinical development of a medicine.

Micar Innovation received the CIDIC award for its well-chosen positioning in a complex and long value chain, where it can create key-value contributions by delivering non-clinical POCs. The company can be qualified as a fountain of intellectual property and an IP broker for new pharma startups and big pharma industry.

In computer-aided drug design (CADD), the ultimate goal is to be able to predict accurately how strongly a potential drug compound will bind to a protein target (i.e., the compound’s binding affinity). Micar21 Drug Discovery platform able to do this, drug discovery to be significantly accelerated, since we would only need to synthesize in the lab those compounds with predicted high affinity for the target of interest (and predicted low affinity for proteins we didn’t want to interfere with).

Discover our Pipeline

We have our own drug discovery programs and our lead compounds are already in Drug Discovery & Preclinical studies. Our strategy is to develop drug for both: humans and companion animals.
*It takes about 7-12 months to obtain a license for companion animals drug.

Project: 110 new treatments of rare and ultra rare diseases by 2030 by our Drug Discovery De-Risk Business Model